English (UK)Português (BR)
Log in

Login to your account

Username *
Password *
Remember Me
Print

Tech Transfer

PLAN FOR TECHNOLOGY TRANSFER

Maria Carolina Quartim Elias-Sabbaga, Coordinator

 

 

PREVIOUS INITIATIVE, TENTATIVENESS AND PITFALLS 

The CATcepid project spearheaded an initiative to streamline procedures for intellectual protection and technology transfer in government institutions such as the Butantan Institute, which is affiliated to the São Paulo State Secretary of Health. This initiative was excellent as a learning experience for all leading investigators involved in the project. But, it encountered insurmountable difficulties because of the lack of policy regarding to intellectual properties on several public Institutions, the Butantan Institute among then. Consequently, the patents of molecules - originated from the partnership between CAT/CEPID and the consortium of pharmaceutical industries - have not reached the formulation of business plans in order to develop these innovations. However, these institutional limitations were recently surpassed because the governmental Decree # 56.569/2010 attributed the status of ICTESP to Butantan Institute. Under this new status, the Butantan Institute organized a NTI (Nucleus for Technological Innovation) and  established Guidelines to deal with technology transfer. 

 

TECHNOLOGY TRANSFER COMING OF AGE

The first attempts of the CATcepid to deal with technological spinoffs from scientific research triggered a learning process among project investigators that progressively created, in house, a culture of innovation. Actually, the development of the patents prematurely licensed to pharmaceutical industries has continued being developed aiming to reach firm proofs of concept or pre-clinical assays.Several of these patented molecules display analgesic, antitumor and tissue remodeling activities.

Nowadays, the leader investigators of this new Center are much better prepared to deal with technological spinoffs from the in house scientific research than 10 years ago. The investigators are also aware that technology transfer to public and private commercial enterprises requires mediation by specialized professionals. This kind of operation should be conducted by an institutional office with expertise in this trading; hopefully, the Instituto Butantan currently has an office (NIT) focused in the  intellectual properties generated in the Butantan Institute. On the other hand, the investigators have also learned that innovation inventors must be sufficiently knowledgeable to actively follow and, eventually, participate in actions for protection of intellectual property, patenting and patent licensing.

 

PRESENT AND FUTURE TRAINING COURSES 

Ana Marisa Chudzinski-Tavassi and Yara Cury, organized a formal discipline on “Development of molecules with potential therapeutic value” within the Post-graduation Toxinology Program of the Butantan Institute. This discipline was the first of its kind in São Paulo or, even, Brazil and the results were excellent, especially because of the collaboration of professionals from private enterprises during the course. 

In the last year, Ana Marisa Chudzinski-Tavassi proposed a MBA course at Butantan Institute, named “Manegement of innovation in health”, a semi presencial course using the based learning method, presencial classes and videoconferences, chats and games. The course has duration of  18 months , covered by 3 cycles (Intelectual property,  Processes and Products, Management of projects and entrepreunership.  The aim for this MBA is to train professionals able to make the connection between academic and productive sectors, between industries and regulatory offices, Academy and law offices, etc. The intention of both initiatives was a pilot testing aiming to training courses which will be offered to our investigators and PhD students and, also, to outside professionals. 

 

PRESENT AND FUTURE INITIATIVES IN TECH TRANSFER 

Former experiences have habilitated our PIs to presently keep under way interesting cases of tech transfer involving specific patents: a) Amblyomin and Lopap with, respectively, União Química and Biolab companies, both under Ana Marisa Chudzinski-Tavassi. Nowadays the  Amblyomin project received grants from BNDES to pre clinical assays and also to development of an industrial process; b) ENPAK with Biolab and under Yara Cury; c) Silica adjuvant vector (SBA-15) with the Cristalia industry, under Osvaldo A. Sant’Anna; d) Immunossupressive Factor from Lachesis muta venom with the Cristalia industry and under the coordination of Denise Tambourgi.

 

In addition, we have now examples of efficient transference between our labs and the industrial sections of Butantan Institute: a) Osvaldo A. Sant’Anna is supervising the application of the Silica adjuvant vector (SBA-15) in the prodution of antivenom sera and, also, in development of oral vaccines and b) Inácio Junqueira de Azevedo has sequenced genomes of bacteria important in the production of vaccines. 

Taking into account our previous experience above summarized, the CETICs  technology transfer intends work as follows: 

i. The Center’s infrastructure comprises state of the art laboratories for scientific research (transcriptomics, proteomics, molecular cell biology and Zebrafish biology) and laboratories of biotechnological development operating under GLP (recombinant protein production, peptide synthesis, cell and animal based bioassays). This infrastructure was designed to foster a virtuous flow of: promising scientific results _ technological development _ technology transfer. 

ii. Several of our sub-projects will likely yield promising scientific results for technological development, which will be analyzed in test of proofs of concept for applied innovations. Only innovations with robust results of proofs of concept will be considered for technology transfer. 

The priorities for technology transfer will be: first, industrial sections of the Instituto Butantan and, second, external public or private industries. Patent licensing or other forms of partnership with external enterprises will follow the Guidelines of Butantan Institute for technology transfer, taking also in account clauses from the contract between FAPESP and Butantan Institute. In addition, rights from the inventors will be protected according to the Law of Innovation.

 

 

ScanTECHTRANSFER

 Figure1. Flowchart of the process for technology development

tech1tech2tech3tech4tech5tech6tech7

 

 

1-PATENTS APPLICATIONS

Process

Title

Deposit date

Inventors

INPI-BR 10 2013 027648 0 A2

POLYNUCLEOTIDE, POLYPEPTIDE WITH IMMUNOSUPPRESSIVE ACTIVITY, EXPRESSION CASSETTE, EXPRESSION VECTOR, HOST CELL, PHARMACEUTICAL COMPOSITION, METHODS FOR PRODUCING A POLIPEPTIDE WITH IMMUNOSUPPRESSIVE ACTIVITY AND TO PREVENT OR TO TREAT CONDITIONS THAT NEED IMMUNOSUPPRESSION, AND, USE OF A POLIPEPTIDE

2013

DENISE V. TAMBOURGI / GISELLE PIDDE QUEIROZ / OSVALDO AUGUSTO BRAZIL ESTEVES SANT'ANNA / FÁBIO CARLOS MAGNOLI / OGARI DE CASTRO PACHECO

INPI-BR 10 2013 031043 3 A2

USE OF CHEMICALS ABLE TO INHIBIT THE TOXIC ACTION OF SFINGOMIELINASE DERIVATIVES AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE REFERRED COMPOUNDS

2013

DENISE VILARINHO TAMBOURGI / PRISCILA HESS LOPES / MARIO TYAGO MURAKAMI / RUTE MARIA GONÇALVES DE ANDRADE

China (CN101511861), Índia (IN256624), Hong Kong (HK1135406), Canadá (CA2657338), Coreia (PI0602885-3) e Japão (JP5635771)

TnP - Thalassophryne nattereri peptIde

China (24.04.2013), Índia (09.07.2013), Hong Kong (19.09.2013), Canadá (22.10.2013), Coreia (28.01.2014) e Japão (18.11.2014)

Mônica Valdyrce dos Anjos Lopes Ferreira / Carla Lima da Silva / Daniel Carvalho Pimenta / Kátia da Conceição / Marilene Demasi   / Fernanda Calheta Vieira Portaro

INPI-BR 10 2016 017666 2

"COMPOSITION, AND, USE OF A PEPTIDE".

2016

MARIA CAROLINA QUARTIM BARBOSA ELIAS SABBAGA e CHRISTIANE BEZERRA DE ARAUJO

INPI # BR

BR 10 2016 023153 1

Usage of Crotalphine in neurodegenerative diseases (MMM/PN006536)

2016

GISELE PICOLO AND YARA CURY

INPI # BR 102017005783-6

Sculpitin

2017

ASIF IQBAL, MAURICIO BARBUGIANI GOLDFEDER AND ANA MARISA CHUDZINSKI-TAVASSI

2- SOFTWARES

Softwares

Information

Signaling Network Simulator (SigNetSim)

User-friendly, web-based tool that allows the design and simulation of kinetic models of cell signaling networks. SigNetSim was coded in Python, is free software under the AGPL license and can be downloaded at: https://github.com/vincent-noel/SigNetSim;

Cell Cycle Duration (CeCyD)

Web-based tool to estimate the duration of each cell cycle phases.

Amalgam of Repositories and Tools for Identification of Signaling Networks. (ARTISiN)

This is an under development platform, whose objective is to integrate omics repositories (e.g. CeTICSdb) and tools for modeling of cell signaling networks (e.g. SigNetSim) through a multi-agent system.

3-  DATABASE

CeTICS database (CeTICSdb): a web-based repository to provide storage and integration of low and high-throughput, heterogeneous omics data. CeTICSdb has a hierarchical access control to ensure privacy and different levels of data security. This repository, which was also coded in Python and also is available under the AGPL license, can be accessed at: http://cetics.butantan.gov.br/ceticsdb.

This email address is being protected from spambots. You need JavaScript enabled to view it.

logo-fapesp